Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

NCT05553093 on ClinicalTrials.gov · last registry update 2022-09-23

An unusually large phase 4: 150 participants, more than double the 75 typical for the stage. Its estimated completion date, 31 December 2023, has passed with no update to the record. Primary outcome, as filed: blood sugar changes. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. tirzepatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Nanjing First Hospital, Nanjing Medical University
Sponsor type: Other
Enrollment: 150
Started: 2022-03-15
Primary completion: 2023-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

blood sugar changes

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.